Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle cell lymphoma.

P J Kurtin1

  • 1Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA.

Advances in Anatomic Pathology
|March 30, 1999
PubMed
Summary
This summary is machine-generated.

Mantle cell lymphoma (MCL) is a rare non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic amyloidosis from A (AA) to T (ATTR): a review.

Journal of internal medicine·2020
Same author

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.

Leukemia·2011
Same author

Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets.

Leukemia·2010
Same author

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.

Leukemia·2008
Same journal

Pathobiology and Interactions of the MiTF Signaling Pathways.

Advances in anatomic pathology·2026
Same journal

Diagnosis and Reporting of Intraductal Carcinoma of the Prostate: A Guide for Practising Pathologists With Excerpts From the Genitourinary Pathology Society and the International Society of Urological Pathology Joint Expert Consultation.

Advances in anatomic pathology·2026
Same journal

An Update on Soft Tissue Tumors of the Paratesticular Region.

Advances in anatomic pathology·2026
Same journal

Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management.

Advances in anatomic pathology·2026
Same journal

Hereditary and Familial Tumor Syndromes: When to Think of Them? The Emerging Role of Pathologists as Sentinels of Genetic Cancer Predisposition.

Advances in anatomic pathology·2026
Same journal

From Familial Clustering to a Dedicated Classification: The Historical Recognition of Hereditary Tumor Syndromes in the WHO Classification of Tumors.

Advances in anatomic pathology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Mantle cell lymphoma (MCL) constitutes 2-8% of non-Hodgkin's lymphoma (NHL) in the US.
  • MCL typically affects older males, presenting with generalized lymphadenopathy and often disseminated disease.
  • Pathologically, MCL involves small lymphocytes with irregular nuclei and clumped chromatin, exhibiting nodular or diffuse growth patterns.

Purpose of the Study:

  • To detail the pathological, phenotypic, and genetic characteristics of mantle cell lymphoma.
  • To highlight diagnostic markers for distinguishing MCL from other low-grade B-cell lymphomas.
  • To provide a comprehensive overview of MCL for clinical and research purposes.

Main Methods:

  • Morphological analysis of lymph node and bone marrow biopsies.

Related Experiment Videos

  • Immunophenotypic profiling using flow cytometry and immunohistochemistry.
  • Genetic analysis to identify characteristic chromosomal translocations, such as t(11;14).

    • Main Results:

    • MCL cells express pan B-cell antigens, CD5, and CD43, while being negative for CD10 and CD23.
    • The translocation t(11;14) leading to cyclin-D1 overexpression is a hallmark of many MCL cases.
    • Immunohistochemistry for cyclin-D1 aids in differentiating MCL from other small B-cell lymphomas.

    Conclusions:

    • Mantle cell lymphoma has distinct pathological, immunophenotypic, and genetic features.
    • Accurate diagnosis relies on a combination of morphology, immunophenotyping, and genetic analysis.
    • Distinguishing MCL from other low-grade B-cell lymphoproliferative disorders is crucial for appropriate patient management.